Affinity Asset Advisors, LLC Chinook Therapeutics, Inc. Call Options Transaction History

Affinity Asset Advisors, LLC

  • $596 Million
  • Q2 2025

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding KDNY

# of Institutions
3
Shares Held
234K
Call Options Held
0
Put Options Held
0
View Full List

About CHINOOK THERAPEUTICS, INC.

KDNY Quotes by TradingView
  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email